ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 Neoadjuvant HER2-Targeted Therapy +/- Immunotherapy With Pembrolizumab: An Open Label Randomized Phase 2 Trial
By
ASCO 2022 Conference Coverage
FEATURING
Heather McArthur
By
ASCO 2022 Conference Coverage
FEATURING
Heather McArthur
82 views
June 16, 2022
Login to view comments.
Click here to Login
Breast